The tissue diagnostics market is projected to reach $8.52 billion by 2029, at a CAGR of 7.4% from 2022 to 2029.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities. The growth in the tissue diagnostics market is attributed to the rising prevalence of cancer globally, the availability of biomarkers and research on biomarkers, recommendations for cancer screening, the growing number of clinical trials for oncology drugs, and the availability of tissue-based companion diagnostics. Additionally, emerging economies, growing developments in personalized medicines, and the shift towards automation are likely to offer significant growth opportunities for the tissue diagnostics market.
Based on product type, in 2022, the consumables segment is expected to account for the largest share of the market. The key factors attributing to the large market share of this segment are the repetitive need for consumables and technological advances in developing novel consumables. For instance, in May 2022, Qiagen N.V. (Netherlands) launched its therascreen EGFR Plus RGQ PCR Kit, a new in-vitro diagnostic test for sensitive EGFR mutation analysis. It detects all the currently known activating and resistance EGFR mutations.
Based on technology, in 2022, the immunohistochemistry segment is expected to account for the largest share of the market. Immunohistochemistry provides variations between different types of tumors over conventional enzyme staining techniques; thus, the adoption of IHC for conducting immunodiagnostics tests and point-of-care diagnostic tests for tissue diagnostics is high. This contributes to the large market share of this segment.
Based on application, the tissue diagnostics market is segmented into breast cancer, lung cancer, colorectal and gastrointestinal cancer, prostate cancer, lymphatic cancer, and others. In 2022, the breast cancer segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the high prevalence of breast cancer and the presence of several research and screening programs. For instance, in October 2021, The Breast Cancer Research Foundation (BCRF) announced USD 47.5 million in funding to support breast cancer research during 2021-22.
Based on end user, in 2022, the hospitals and reference laboratories segment is expected to account for the largest share of the market. The rising prevalence of cancer globally and the subsequent high inflow of patients to hospitals and reference laboratories support the large market share of this segment.
An in-depth analysis of the geographical scenario of the tissue diagnostics market provides detailed qualitative and quantitative insights into five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2022, North America is expected to account for the largest share of the tissue diagnostics market. The high incidence rate of cancer, access to a number of public programs to minimize cancer incidence, technological advancements, and the adoption of personalized medicine attribute to the large market share of this regional market.
Some of the key players operating in the global tissue diagnostics market are F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Sigma-Aldrich Co. LLC) (Germany), Sakura Finetek Japan Co., Ltd. (Japan), Abcam plc (U.K.), Becton, Dickinson, and Company (U.S.), QIAGEN N.V. (Netherlands), Cell Signaling Technology, Inc. (U.S.), Bio-Genex Laboratories, Inc. (U.S.), Bio SB, INC (U.S.), 3DHISTECH Ltd. (Hungary), and HOLOGIC, INC. (U.S.).
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities. The growth in the tissue diagnostics market is attributed to the rising prevalence of cancer globally, the availability of biomarkers and research on biomarkers, recommendations for cancer screening, the growing number of clinical trials for oncology drugs, and the availability of tissue-based companion diagnostics. Additionally, emerging economies, growing developments in personalized medicines, and the shift towards automation are likely to offer significant growth opportunities for the tissue diagnostics market.
Based on product type, in 2022, the consumables segment is expected to account for the largest share of the market. The key factors attributing to the large market share of this segment are the repetitive need for consumables and technological advances in developing novel consumables. For instance, in May 2022, Qiagen N.V. (Netherlands) launched its therascreen EGFR Plus RGQ PCR Kit, a new in-vitro diagnostic test for sensitive EGFR mutation analysis. It detects all the currently known activating and resistance EGFR mutations.
Based on technology, in 2022, the immunohistochemistry segment is expected to account for the largest share of the market. Immunohistochemistry provides variations between different types of tumors over conventional enzyme staining techniques; thus, the adoption of IHC for conducting immunodiagnostics tests and point-of-care diagnostic tests for tissue diagnostics is high. This contributes to the large market share of this segment.
Based on application, the tissue diagnostics market is segmented into breast cancer, lung cancer, colorectal and gastrointestinal cancer, prostate cancer, lymphatic cancer, and others. In 2022, the breast cancer segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the high prevalence of breast cancer and the presence of several research and screening programs. For instance, in October 2021, The Breast Cancer Research Foundation (BCRF) announced USD 47.5 million in funding to support breast cancer research during 2021-22.
Based on end user, in 2022, the hospitals and reference laboratories segment is expected to account for the largest share of the market. The rising prevalence of cancer globally and the subsequent high inflow of patients to hospitals and reference laboratories support the large market share of this segment.
An in-depth analysis of the geographical scenario of the tissue diagnostics market provides detailed qualitative and quantitative insights into five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2022, North America is expected to account for the largest share of the tissue diagnostics market. The high incidence rate of cancer, access to a number of public programs to minimize cancer incidence, technological advancements, and the adoption of personalized medicine attribute to the large market share of this regional market.
Some of the key players operating in the global tissue diagnostics market are F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Sigma-Aldrich Co. LLC) (Germany), Sakura Finetek Japan Co., Ltd. (Japan), Abcam plc (U.K.), Becton, Dickinson, and Company (U.S.), QIAGEN N.V. (Netherlands), Cell Signaling Technology, Inc. (U.S.), Bio-Genex Laboratories, Inc. (U.S.), Bio SB, INC (U.S.), 3DHISTECH Ltd. (Hungary), and HOLOGIC, INC. (U.S.).
Scope of the Report:
Global Tissue Diagnostics Market, by Product Type
- Consumables
- Antibodies
- Kits
- Reagents
- Instruments
- Slide Staining Systems
- Slide Scanners
- Tissue Processors
- Other Instruments
- Global Tissue Diagnostics Market, by Technology
- Immunohistochemistry (IHC)
- In-situ Hybridization (ISH)
- Digital Pathology
- H&E Slide Staining
- Other Technologies
- Global Tissue Diagnostics Market, by Application
- Breast Cancer
- Lung Cancer
- Colorectal and Gastrointestinal Cancer
- Prostate Cancer
- Lymphatic Cancer
- Other Applications
- Global Tissue Diagnostics Market, by End User
- Hospitals and Reference Laboratories
- Research Institutes
- Pharmaceutical Companies
- Contract Research Organization
Global Tissue Diagnostics Market, by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. Tissue Diagnostics Market, by Product Type
6. Tissue Diagnostics Market, by Technique
7. Tissue Diagnostics Market, by Application
8. Tissue Diagnostics Market, by End User
9. Tissue Diagnostics Market, by Geography
10. Competitive Landscape
11. Company Profiles
12. Appendix
List of Tables
List of Figures
Companies Mentioned
- F. Hoffmann-La Roche Ltd (Switzerland)
- Danaher Corporation (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Abbott Laboratories (U.S.)
- Agilent Technologies Inc. (U.S.)
- Merck KGaA (Sigma-Aldrich Co. LLC) (Germany)
- Sakura Finetek Japan Co. Ltd. (Japan)
- Abcam plc (U.K.)
- Becton Dickinson and Company (U.S.)
- QIAGEN N.V. (Netherlands)
- Cell Signaling Technology Inc. (U.S.)
- Bio-Genex Laboratories Inc. (U.S.)
- Bio SB Inc (U.S.)
- 3DHISTECH Ltd. (Hungary)
- HOLOGIC Inc. (U.S.).
